Posted by Michael Wonder on 09 Mar 2021
NICE rejects AZ’s Lynparza for metastatic prostate cancer
9 March 2021 - The UK’s NICE appraisal committee has chosen not to recommend AstraZeneca’s PARP inhibitor Lynparza for BRCA-positive metastatic prostate cancer.
Lynparza (olaparib) is intended for the treatment of hormone-relapsed metastatic prostate cancer with BRCA1/2 mutations that has progressed after abiraterone or enzalutamide treatment in adults.
